[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"DFI Co., Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":91},{"warningLetters":4,"total":90},[5,31,52,74],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},865,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-06T04:00:00Z\">05\u002F06\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdfi-co-ltd-705464-05062025\">DFI Co., Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeong-Hee Jang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DFI Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>388-25 Gomo-Ro Jillye-Myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gimhae-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gyeongsangnam-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>50875\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@dficare.com\"> (b)(6)@dficare.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 6, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jang,\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Gimhae, Gyeongsangnam, Korea on January 6, 2025 through January 9, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CYBOW 11 Reagent Strips for Urinalysis (CYBOW 11). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Ms. Yong-Ae Park, Chief Research and Development Manager, dated January 23, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s 2022 to 2024 complaint logs showed that not all complaints were entered into your firm’s complaint handling system for evaluation, investigation, and MDR evaluation. For example, the following complaints involving the possible failure of the device to meet any of its specifications were not entered:\u003C\u002Fp>\u003Cp>a. Analyzer complaint #60 in 2022 was received on January 17, 2022, due to “Leukocyte shows false negative, Nitrite shows false positive;”\u003C\u002Fp>\u003Cp>b. Strip complaint #16 in 2022 was received on August 4, 2022, due to “All parameters are showing positive results;”\u003C\u002Fp>\u003Cp>c. Strip complaint #16 in 2023 was received on May 19, 2023, due to “False negative for Blood;”\u003C\u002Fp>\u003Cp>d. Analyzer complaint #6 in 2024 was received on January 15, 2024, due to “After dipping in water, Bld\u002FNit\u002FLeu appear false positive;” and\u003C\u002Fp>\u003Cp>e. Strip complaint #25 in 2024 was received on December 3, 2024, due to “High concentration shows delayed or no color development.”\u003C\u002Fp>\u003Cp>Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that many of the complaints were not entered into the complaint handling system because they were handled informally by the sales department.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm identified the root cause of the problem as, “the reason for not issuing the report is not clearly indicated, so we have updated it by adding it to the procedures.” Your firm’s response did not include a description or evidence that the specific complaints identified in the FDA 483 have been investigated. Your firm provided DFI-OP-801(V10) titled Customer complaints. While your firm noted that you updated your procedure to include situations where customer complaint reports would not be issued, the updated procedure document is inadequate. The procedure does not ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1); it does not include timeframes for evaluating and reviewing complaints. Specifically, it does not ensure that complaints which require a 5-day or 30-day report in accordance with 21 CFR Part 803 are evaluated in a timely manner. Additionally, the updated customer complaint document allows for specific complaints involving the possible failure of the device to meet its specifications to not be reviewed, evaluated, and investigated (e.g., when abnormal color development is caused by the interfering substances mentioned in the insert). This procedure, allowing for such complaints to not be reviewed, evaluated, or investigated, does not meet the requirement of 21 CFR 820.198(c).\u003C\u002Fp>\u003Cp>Once an adequate complaint handling procedure is established your firm should provide evidence of training on the new procedure for all personnel who may receive complaints, including the sales department. Additionally, your firm should conduct a retrospective review to determine if corrections are needed in response to other complaints involving the possible failure of the device, labeling, or packaging to meet any of their specifications which were not appropriately investigated. A summary of the findings and a remediation plan, if necessary, should be provided.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain adequate procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90. For example:\u003C\u002Fp>\u003Cp>a. The investigator noted that during manufacture of the protein reagent (used in the manufacturing of the CYBOW 11), that the reagent failed the pH test three times but only the third failure \u003Cstrong>(b)(4)\u003C\u002Fstrong> was documented in the production record. Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that the technician did not believe in the failed results, and therefore, he repeated the tests.\u003C\u002Fp>\u003Cp>b. Page 6, Section 5 (subtitled 1st QC check) of the manufacturing process technical file provided during the investigation shows that your firm allows for a recheck of failed QCs during this stage of the workflow (1st QC check).\u003C\u002Fp>\u003Cp>c. Page 15, Section 12 (subtitled 3rd QC check) of the manufacturing process technical file provided during the investigation shows that your firm allows for a recheck of failed QCs during this stage of the workflow (3rd QC check).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. With regards to the retesting failed pH values, your firm indicated that you revised your documentation (DFI-WIC-014(V2) Reagent manufacture_20250113) to include instructions that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, the revision instructs \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While the revision to the reagent manufacture document addresses the identification, documentation, and evaluation of the nonconformance, it does not address segregation and disposition of the nonconforming product, nor does it specify whether the evaluation and any investigation shall be documented, as required by 21 CFR 820.90 (a). Additionally, your firm has not provided evidence to support that you have procedures that define the responsibility for review and the authority for the disposition of nonconforming product. The procedures must include instruction that disposition of nonconforming product shall be documented and shall include the justification for use of nonconforming product and the signature of the individual(s) authorizing the use, as required by 21 CFR 820.90 (b)(1).\u003C\u002Fp>\u003Cp>Your firm stated in your response, for the 1st QC check (described in the cover letter as semi-product), that, “ \u003Cem>If the result of the actual QC Inspection (Semi-Product(I) fails, we do not reconfirm, but it is incorrectly recorded in the Manufacturing Process and corrected\u003C\u002Fem>.” Your firm provided the revised document titled, “2-TCF31D0-10_Manufacture process \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, item 2, section 5.5 in this document subtitled, “Processing of Inspection LOT” states, “\u003Cem>Rejected Lot: \u003Cu>If passed after a retest\u003C\u002Fu>, it is put into the next process and discarded when rejected\u003C\u002Fem>,” (emphasis added). Therefore, this response is inadequate because the revised document still includes language that allows users to retest without requiring that the nonconformance be evaluated and a determination of the need for an investigation be made in accordance with 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>As pertains to the 3rd QC check, your firm indicated in your response that this stage relates to the finished product and looks at two things: the test paper, and the packaging. Your firm indicates that if there is a problem with the test paper, you would \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm provided the revised manufacturing process document and your nonconformity procedure to support this response. The revised manufacturing process document now states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the nonconformity product management document provided in your firm’s response includes a reference to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, the documentation provided by your firm does not require that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including a determination of any adverse effect from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> the product, shall be documented in the device history record, as required by 21 CFR 820.90(b)(2). Further, your firm did not include reference to systemic corrective actions to ensure that adequate procedures are in place to control all product that does not conform to specified requirements as required by 21 CFR 820.90.\u003C\u002Fp>\u003Cp>Once an adequate nonconforming product procedure is established, your firm should provide evidence of training on the new procedures. Additionally, your firm should conduct a retrospective review to determine if other nonconforming product was appropriately handled. A summary of the findings and a remediation plan, if necessary, should be provided.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain adequate procedures to control labeling activities, as required by 21 CFR 820.120. Specifically, your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that your firm does not have a written procedure to control labeling activities, and that your firm’s device history records (DHR) do not include or refer to the location of the primary identification labeling nor the unique device identifiers (UDI) used for each production unit\u002Flot\u002Fbatch for the CYBOW 11. The DHRs reviewed during the investigation did not include or refer to the location of the label and labeling used (primary label\u002FUDI label) for each production unit\u002Flot\u002Fbatch. Ms. Yong-Ae Park informed the investigator that she did not know that the primary labeling (including UDIs) needs to be included as part of the DHRs.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm provided documentation indicating that you added information relating to labeling to your inspection standard forms for raw and finished products related to the CYBOW 11, as well as an import inspection certificate for the label and a QC inspection report form with a location for the label. Your firm also provided documentation from a specific lot showing the implemented changes as well as training records demonstrating that staff have been trained on the inspection of finished products. However, while the documents mention label integrity, your firm has not provided evidence to show that you have implemented activities to ensure that labels shall be printed and applied so as to remain legible and affixed during the customary conditions of processing, storage, handling, distribution, and where appropriate use as required by 21 CFR 820.120(a).\u003C\u002Fp>\u003Cp>Additionally, your firm’s test inspection standard, which applies to the finished product, does not include information to show, as required by 21 CFR 820.120(b), that the labeling shall not be released for storage or use until a designated individual(s) has examined the labeling for accuracy including, where applicable, the correct UDI or universal product code (UPC), expiration date, control number, storage instructions, handling instructions, and any additional processing instructions. It also does not require that the release, including the date and signature of the individual(s) performing the examination, be documented in the DHR. Also, the documentation provided does not include information on labeling storage as required by 21 CFR 820.120(c), to support that labeling shall be stored in a manner that provides proper identification and is designed to prevent mix-ups.\u003C\u002Fp>\u003Cp>Further, the response is inadequate because your firm did not include reference to systemic corrective actions to ensure that you have procedures to control labeling activities for products other than the CYBOW 11, as required by 21 CFR 820.120. Once adequate labeling control procedures are established, your firm should provide evidence of training on the new procedures.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of 21 CFR 820.184. For example, per your firm’s mixing procedure forms listed below, technicians are not required to document the time and speed for the mixing procedures for the reagents of the CYBOW 11 reagent strips for urinalysis:\u003C\u002Fp>\u003Cul>\u003Cli>Urobilinogen Operation Procedure\u003C\u002Fli>\u003Cli>Glucose Operation Procedure\u003C\u002Fli>\u003Cli>Bilirubin Operation Procedure\u003C\u002Fli>\u003Cli>Ketones Operation Procedure\u003C\u002Fli>\u003Cli>SG Operation Procedure\u003C\u002Fli>\u003Cli>Blood Operation Procedure\u003C\u002Fli>\u003Cli>PH Operation Procedure\u003C\u002Fli>\u003Cli>Protein Operation Procedure\u003C\u002Fli>\u003Cli>Nitrite Operation Procedure\u003C\u002Fli>\u003Cli>Leukocytes Operation Procedure\u003C\u002Fli>\u003Cli>ASA Operation Procedure\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Specifically, two DHR logs reviewed during the inspection (DHR for Lot 240104 and lot 240619) confirm that technicians do not document the time and speed for the mixing procedures to show that these activities were performed.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm provided operation procedure documents for each of the reagents of the CYBOW 11. While your firm updated your reagent operating procedures with temperature, speed, and time ranges for each step of the process that requires mixing, the updated operating procedure documents are inadequate because you do not demonstrate that the device is manufactured in accordance with the DMR as required by 21 CFR 820.184. Specifically, the updated operating procedure documents do not instruct technicians to document in the production record, the exact temperatures, speed, and times at which you mixed the reagents. The DHR is intended to provide objective evidence that the requirements of the DMR were met and information to facilitate failure investigations and corrective or preventive actions. Lack of detail in the DHR will prevent a manufacturer from adequately investigating nonconformances.\u003C\u002Fp>\u003Cp>Additionally, the response is inadequate because your firm did not include reference to systemic corrective actions to ensure that DHRs for products other than the CYBOW 11 are maintained to demonstrate that they are manufactured in accordance with the DMR and the requirements of 21 CFR 820.184. Once adequate reagent operating procedures are established, your firm should provide evidence of training on the new procedure. Additionally, your firm should conduct a review to determine if all DHRs are complete. A summary of the findings and a remediation plan, if necessary, should be provided.\u003C\u002Fp>\u003Cp>5. Failure to adequately identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86. Specifically, the original production identification (Pass\u002FFail) label used in the manufacture of the CYBOW 11 was not maintained. For example, while the manufacturing process document reviewed during the inspection states that all production processes are documented and controlled, the investigator noted that during manufacturing, the label used to track the reagent to show it was approved for use by QC is discarded after the product is moved to the next process. Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that the label is discarded once the reagent is moved to the next process.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your response, your firm addressed the observation by providing multiple updated documents including: (i) the standard operating procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> processes, with added language to ensure that users confirm the presence of the QC approval seal, (ii) \u003Cstrong>(b)(4) \u003C\u002Fstrong>working forms, with a check box added to confirm the Lot number and QC acceptance for the dipping work product, and (iii) training forms to show that users were trained on the revised steps. However, the response is inadequate because your firm did not conduct a review to ensure that products other than the CYBOW 11 are also subjected to adequate acceptance status activities. A summary of the findings and a remediation plan, if necessary, should be provided.\u003C\u002Fp>\u003Cp>\u003Cstrong>Medical Device Reporting (MDR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. For example: during the inspection, your firm presented the document titled “FDA Medical Decivice [sic] Reporting”, DFI‐OP‐816, Revision No. 1, dated 2023.05.01 as its written MDR procedure. Upon review, we conclude that the procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definition of the term “malfunction” from 21 CFR 803.3(k), and fails to specify what kind of information “reasonably suggests” that an MDR reportable event has occurred per 21 CFR 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. The response includes a copy of your firm’s revised MDR procedures titled “FDA Medical Decivice [sic] Reporting”, DFI‐OP‐816, Revision No. 2, dated 2025.01.15. Upon review of the revision, we note that it still fails to specify what kind of information “reasonably suggests” that an MDR reportable event has occurred per 803.20(c)(1). Additionally, we encourage your firm to conduct a retrospective review to determine if corrections are needed for other complaints involving the possible failure of the device, labeling, or packaging to meet any of their specifications which were not appropriately investigated for reportability.\u003C\u002Fp>\u003Cp>We note that a device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the device, including adverse event reports required under 21 CFR Part 803.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 705464 when replying. If you have any questions about the contents of this letter, please contact: Christine Kilonzo at Christine.kilonzo@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the\u003C\u002Fp>\u003Cp>Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>Director\u003Cbr>OHT 7: Office of In Vitro Diagnostic Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Ms. Young Ae Park\u003Cbr>Chief Research and Development Manager DFI Co., Ltd.\u003Cbr>\u003Cstrong>(b)(6)\u003C\u002Fstrong>@dficare.com\u003C\u002Fp>\u003Cp>Priscilla Chung\u003Cbr>LK Consulting Group USA, Inc.\u003Cbr>US Agent\u003Cbr>juhee.c@lkconsultinggroup.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeong-Hee Jang\n\nRecipient Title\n\nPresident and CEO\n\nDFI Co., Ltd.\n\n388-25 Gomo-Ro Jillye-Myeon\n\nGimhae-si\n\nGyeongsangnam-do\n\n50875\n\nSouth Korea\n\n(b)(6)@dficare.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nMay 6, 2025\nDear Mr. Jang,\nDuring an inspection of your firm located in Gimhae, Gyeongsangnam, Korea on January 6, 2025 through January 9, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CYBOW 11 Reagent Strips for Urinalysis (CYBOW 11). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yong-Ae Park, Chief Research and Development Manager, dated January 23, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s 2022 to 2024 complaint logs showed that not all complaints were entered into your firm’s complaint handling system for evaluation, investigation, and MDR evaluation. For example, the following complaints involving the possible failure of the device to meet any of its specifications were not entered:\na. Analyzer complaint #60 in 2022 was received on January 17, 2022, due to “Leukocyte shows false negative, Nitrite shows false positive;”\nb. Strip complaint #16 in 2022 was received on August 4, 2022, due to “All parameters are showing positive results;”\nc. Strip complaint #16 in 2023 was received on May 19, 2023, due to “False negative for Blood;”\nd. Analyzer complaint #6 in 2024 was received on January 15, 2024, due to “After dipping in water, Bld\u002FNit\u002FLeu appear false positive;” and\ne. Strip complaint #25 in 2024 was received on December 3, 2024, due to “High concentration shows delayed or no color development.”\nYour firm’s representative, Ms. Yong-Ae Park, stated to the investigator that many of the complaints were not entered into the complaint handling system because they were handled informally by the sales department.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm identified the root cause of the problem as, “the reason for not issuing the report is not clearly indicated, so we have updated it by adding it to the procedures.” Your firm’s response did not include a description or evidence that the specific complaints identified in the FDA 483 have been investigated. Your firm provided DFI-OP-801(V10) titled Customer complaints. While your firm noted that you updated your procedure to include situations where customer complaint reports would not be issued, the updated procedure document is inadequate. The procedure does not ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1); it does not include timeframes for evaluating and reviewing complaints. Specifically, it does not ensure that complaints which require a 5-day or 30-day report in accordance with 21 CFR Part 803 are evaluated in a timely manner. Additionally, the updated customer complaint document allows for specific complaints involving the possible failure of the device to meet its specifications to not be reviewed, evaluated, and investigated (e.g., when abnormal color development is caused by the interfering substances mentioned in the insert). This procedure, allowing for such complaints to not be reviewed, evaluated, or investigated, does not meet the requirement of 21 CFR 820.198(c).\nOnce an adequate complaint handling procedure is established your firm should provide evidence of training on the new procedure for all personnel who may receive complaints, including the sales department. Additionally, your firm should conduct a retrospective review to determine if corrections are needed in response to other complaints involving the possible failure of the device, labeling, or packaging to meet any of their specifications which were not appropriately investigated. A summary of the findings and a remediation plan, if necessary, should be provided.\n2. Failure to establish and maintain adequate procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90. For example:\na. The investigator noted that during manufacture of the protein reagent (used in the manufacturing of the CYBOW 11), that the reagent failed the pH test three times but only the third failure (b)(4) was documented in the production record. Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that the technician did not believe in the failed results, and therefore, he repeated the tests.\nb. Page 6, Section 5 (subtitled 1st QC check) of the manufacturing process technical file provided during the investigation shows that your firm allows for a recheck of failed QCs during this stage of the workflow (1st QC check).\nc. Page 15, Section 12 (subtitled 3rd QC check) of the manufacturing process technical file provided during the investigation shows that your firm allows for a recheck of failed QCs during this stage of the workflow (3rd QC check).\nWe reviewed your firm’s response and conclude that it is not adequate. With regards to the retesting failed pH values, your firm indicated that you revised your documentation (DFI-WIC-014(V2) Reagent manufacture_20250113) to include instructions that (b)(4). Additionally, the revision instructs (b)(4). While the revision to the reagent manufacture document addresses the identification, documentation, and evaluation of the nonconformance, it does not address segregation and disposition of the nonconforming product, nor does it specify whether the evaluation and any investigation shall be documented, as required by 21 CFR 820.90 (a). Additionally, your firm has not provided evidence to support that you have procedures that define the responsibility for review and the authority for the disposition of nonconforming product. The procedures must include instruction that disposition of nonconforming product shall be documented and shall include the justification for use of nonconforming product and the signature of the individual(s) authorizing the use, as required by 21 CFR 820.90 (b)(1).\nYour firm stated in your response, for the 1st QC check (described in the cover letter as semi-product), that, “ If the result of the actual QC Inspection (Semi-Product(I) fails, we do not reconfirm, but it is incorrectly recorded in the Manufacturing Process and corrected.” Your firm provided the revised document titled, “2-TCF31D0-10_Manufacture process (b)(4).” However, item 2, section 5.5 in this document subtitled, “Processing of Inspection LOT” states, “Rejected Lot: If passed after a retest, it is put into the next process and discarded when rejected,” (emphasis added). Therefore, this response is inadequate because the revised document still includes language that allows users to retest without requiring that the nonconformance be evaluated and a determination of the need for an investigation be made in accordance with 21 CFR 820.90(a).\nAs pertains to the 3rd QC check, your firm indicated in your response that this stage relates to the finished product and looks at two things: the test paper, and the packaging. Your firm indicates that if there is a problem with the test paper, you would (b)(4). Your firm provided the revised manufacturing process document and your nonconformity procedure to support this response. The revised manufacturing process document now states “(b)(4)” and the nonconformity product management document provided in your firm’s response includes a reference to “(b)(4)”. However, the documentation provided by your firm does not require that (b)(4), including a determination of any adverse effect from the (b)(4) the product, shall be documented in the device history record, as required by 21 CFR 820.90(b)(2). Further, your firm did not include reference to systemic corrective actions to ensure that adequate procedures are in place to control all product that does not conform to specified requirements as required by 21 CFR 820.90.\nOnce an adequate nonconforming product procedure is established, your firm should provide evidence of training on the new procedures. Additionally, your firm should conduct a retrospective review to determine if other nonconforming product was appropriately handled. A summary of the findings and a remediation plan, if necessary, should be provided.\n3. Failure to establish and maintain adequate procedures to control labeling activities, as required by 21 CFR 820.120. Specifically, your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that your firm does not have a written procedure to control labeling activities, and that your firm’s device history records (DHR) do not include or refer to the location of the primary identification labeling nor the unique device identifiers (UDI) used for each production unit\u002Flot\u002Fbatch for the CYBOW 11. The DHRs reviewed during the investigation did not include or refer to the location of the label and labeling used (primary label\u002FUDI label) for each production unit\u002Flot\u002Fbatch. Ms. Yong-Ae Park informed the investigator that she did not know that the primary labeling (including UDIs) needs to be included as part of the DHRs.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm provided documentation indicating that you added information relating to labeling to your inspection standard forms for raw and finished products related to the CYBOW 11, as well as an import inspection certificate for the label and a QC inspection report form with a location for the label. Your firm also provided documentation from a specific lot showing the implemented changes as well as training records demonstrating that staff have been trained on the inspection of finished products. However, while the documents mention label integrity, your firm has not provided evidence to show that you have implemented activities to ensure that labels shall be printed and applied so as to remain legible and affixed during the customary conditions of processing, storage, handling, distribution, and where appropriate use as required by 21 CFR 820.120(a).\nAdditionally, your firm’s test inspection standard, which applies to the finished product, does not include information to show, as required by 21 CFR 820.120(b), that the labeling shall not be released for storage or use until a designated individual(s) has examined the labeling for accuracy including, where applicable, the correct UDI or universal product code (UPC), expiration date, control number, storage instructions, handling instructions, and any additional processing instructions. It also does not require that the release, including the date and signature of the individual(s) performing the examination, be documented in the DHR. Also, the documentation provided does not include information on labeling storage as required by 21 CFR 820.120(c), to support that labeling shall be stored in a manner that provides proper identification and is designed to prevent mix-ups.\nFurther, the response is inadequate because your firm did not include reference to systemic corrective actions to ensure that you have procedures to control labeling activities for products other than the CYBOW 11, as required by 21 CFR 820.120. Once adequate labeling control procedures are established, your firm should provide evidence of training on the new procedures.\n4. Failure to establish and maintain procedures to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of 21 CFR 820.184. For example, per your firm’s mixing procedure forms listed below, technicians are not required to document the time and speed for the mixing procedures for the reagents of the CYBOW 11 reagent strips for urinalysis:\nUrobilinogen Operation Procedure\nGlucose Operation Procedure\nBilirubin Operation Procedure\nKetones Operation Procedure\nSG Operation Procedure\nBlood Operation Procedure\nPH Operation Procedure\nProtein Operation Procedure\nNitrite Operation Procedure\nLeukocytes Operation Procedure\nASA Operation Procedure\nSpecifically, two DHR logs reviewed during the inspection (DHR for Lot 240104 and lot 240619) confirm that technicians do not document the time and speed for the mixing procedures to show that these activities were performed.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm provided operation procedure documents for each of the reagents of the CYBOW 11. While your firm updated your reagent operating procedures with temperature, speed, and time ranges for each step of the process that requires mixing, the updated operating procedure documents are inadequate because you do not demonstrate that the device is manufactured in accordance with the DMR as required by 21 CFR 820.184. Specifically, the updated operating procedure documents do not instruct technicians to document in the production record, the exact temperatures, speed, and times at which you mixed the reagents. The DHR is intended to provide objective evidence that the requirements of the DMR were met and information to facilitate failure investigations and corrective or preventive actions. Lack of detail in the DHR will prevent a manufacturer from adequately investigating nonconformances.\nAdditionally, the response is inadequate because your firm did not include reference to systemic corrective actions to ensure that DHRs for products other than the CYBOW 11 are maintained to demonstrate that they are manufactured in accordance with the DMR and the requirements of 21 CFR 820.184. Once adequate reagent operating procedures are established, your firm should provide evidence of training on the new procedure. Additionally, your firm should conduct a review to determine if all DHRs are complete. A summary of the findings and a remediation plan, if necessary, should be provided.\n5. Failure to adequately identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86. Specifically, the original production identification (Pass\u002FFail) label used in the manufacture of the CYBOW 11 was not maintained. For example, while the manufacturing process document reviewed during the inspection states that all production processes are documented and controlled, the investigator noted that during manufacturing, the label used to track the reagent to show it was approved for use by QC is discarded after the product is moved to the next process. Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that the label is discarded once the reagent is moved to the next process.\nWe reviewed your firm’s response and conclude that it is not adequate. In your response, your firm addressed the observation by providing multiple updated documents including: (i) the standard operating procedures for the (b)(4) processes, with added language to ensure that users confirm the presence of the QC approval seal, (ii) (b)(4) working forms, with a check box added to confirm the Lot number and QC acceptance for the dipping work product, and (iii) training forms to show that users were trained on the revised steps. However, the response is inadequate because your firm did not conduct a review to ensure that products other than the CYBOW 11 are also subjected to adequate acceptance status activities. A summary of the findings and a remediation plan, if necessary, should be provided.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. For example: during the inspection, your firm presented the document titled “FDA Medical Decivice [sic] Reporting”, DFI‐OP‐816, Revision No. 1, dated 2023.05.01 as its written MDR procedure. Upon review, we conclude that the procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definition of the term “malfunction” from 21 CFR 803.3(k), and fails to specify what kind of information “reasonably suggests” that an MDR reportable event has occurred per 21 CFR 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nWe reviewed your firm’s response and conclude that it is not adequate. The response includes a copy of your firm’s revised MDR procedures titled “FDA Medical Decivice [sic] Reporting”, DFI‐OP‐816, Revision No. 2, dated 2025.01.15. Upon review of the revision, we note that it still fails to specify what kind of information “reasonably suggests” that an MDR reportable event has occurred per 803.20(c)(1). Additionally, we encourage your firm to conduct a retrospective review to determine if corrections are needed for other complaints involving the possible failure of the device, labeling, or packaging to meet any of their specifications which were not appropriately investigated for reportability.\nWe note that a device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the device, including adverse event reports required under 21 CFR Part 803.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 705464 when replying. If you have any questions about the contents of this letter, please contact: Christine Kilonzo at Christine.kilonzo@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the\nInspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nCourtney H. Lias, Ph.D.\nDirector\nOHT 7: Office of In Vitro Diagnostic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nMs. Young Ae Park\nChief Research and Development Manager DFI Co., Ltd.\n(b)(6)@dficare.com\nPriscilla Chung\nLK Consulting Group USA, Inc.\nUS Agent\njuhee.c@lkconsultinggroup.com","DFI Co., Ltd.","dfi-co-ltd-705464-05062025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdfi-co-ltd-705464-05062025","2026-10-26T08:08:24.041965+00:00","Warning Letter","Issued","2025-06-03","705464","Medical Devices","Jeong-Hee Jang","2026-08-19T16:42:13.004+00:00","VIA Electronic Mail","2025-05-06",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":46,"medical_device_id":19,"response_letter_date":19},3032,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-11-09T20:00:00Z\">11\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-09T05:00:00Z\">11\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbadfish-drip-co-619822-11092021\">Badfish Drip Co\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jackie L. Moss\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Badfish Drip Co\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9055 Highway 51 North\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Southaven\u003C\u002Fspan>, \u003Cspan>MS\u003C\u002Fspan> \u003Cspan>38671\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:badfisheliquid@gmail.com\"> badfisheliquid@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 09, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Moss:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Badfish Drip Co. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: BADFISH Drip Co. SASSI ASS FLOAT 03MG 60ML, and BADFISH Drip Co. JACK FROST 03MG 60ML.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 1,300 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002341, on September 09, 2020. However, FDA issued a negative action for STN PM0002341 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 1,172 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002341 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100289, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJackie L. Moss\n\nRecipient Title\n\nOwner\n\nBadfish Drip Co\n\n9055 Highway 51 North\n\nSouthaven, MS 38671\n\nUnited States\n\nbadfisheliquid@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 09, 2021\n\nWARNING LETTER\n\nDear Ms. Moss:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Badfish Drip Co. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: BADFISH Drip Co. SASSI ASS FLOAT 03MG 60ML, and BADFISH Drip Co. JACK FROST 03MG 60ML.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 1,300 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002341, on September 09, 2020. However, FDA issued a negative action for STN PM0002341 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 1,172 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002341 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100289, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Badfish Drip Co","badfish-drip-co-619822-11092021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbadfish-drip-co-619822-11092021","2026-10-26T08:08:00.449263+00:00","2021-11-09","619822","Tobacco","Jackie L. Moss","2026-08-20T02:27:03.054+00:00","VIA UPS and Electronic Mail",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},2403,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2022-10-11T13:20:00Z\">10\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-01T04:00:00Z\">08\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdf-global-inc-633242-08012022\">DF Global, Inc.\u003C\u002Fa>","Division of West Coast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sang Ki Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Branch President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DF Global, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6221 Randolph St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040-3514\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:SK.LEE@DAMTUH.COM\"> SK.LEE@DAMTUH.COM\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 633242\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sang Ki Lee:\u003C\u002Fp>\n\n\u003Cp>On March 30, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of DF Global, Inc., located at 6221 Randolph St, Commerce, CA 90040-3514. We also conducted an inspection on January 15, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: Honey Hallabong Tea, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the FSVP inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response dated April 12, 2022, which stated that you have had an FSVP for all of your imported foods since February 2020 but you did not know which documents to provide during the most recent inspection. Your response also included records associated with your FSVPs for Honey Hallabong Tea, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, such as copies of procedures, a certificate of HACCP Applied Establishment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an audit report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and hazard analyses for Honey Hallabong Tea, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. A hazard means any biological, chemical (including radiological), or physical agent that is reasonably likely to cause illness or injury (see 21 CFR 1.500). A hazard requiring a control means a known or reasonably foreseeable hazard for which a person knowledgeable about the safe manufacturing, processing, packing, or holding of food would, based on the outcome of a hazard analysis (which includes an assessment of the probability that the hazard will occur in the absence of controls or measures and the severity of the illness or injury if the hazard were to occur), establish one or more controls or measures to significantly minimize or prevent the hazard in a food and components to manage those controls or measures (such as monitoring, corrections or corrective actions, verification, and records) as appropriate to the food, the facility, and the nature of the control or measure and its role in the facility’s food safety system (see 21 CFR 1.500). Specifically, in your hazard analysis for “Tea (powder type: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, etc),” which we understand to be for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not identify the chemical hazards of undeclared allergens or natural toxins, such as mycotoxins in peanuts and tree nuts (which includes walnuts and almonds). According to the product labels you provided during the most recent inspection, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are food allergens. Food allergens are reasonably likely to cause illness or injury when undeclared on the package label, such that a control is required to ensure proper labeling. Moreover, you should evaluate whether food allergen controls are required to prevent or significantly minimize allergen cross-contact in the Honey Hallabong Tea and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea products manufactured by the same foreign supplier. You should also evaluate whether mycotoxins in peanuts and tree nuts are a hazard requiring a control for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea. However, you did not provide any information that suggests that food allergens or mycotoxins were identified as hazards requiring a control.\u003C\u002Fp>\n\n\u003Cp>2. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506(e) for the products you import. For an onsite audit, you must retain documentation of each onsite audit, including the audit procedures, the dates the audit was conducted, the conclusions of the audit, any corrective actions taken in response to significant deficiencies identified during the audit, and documentation that the audit was conducted by a qualified auditor (21 CFR 1.506(e)(1)(i)(D)). For a food that is subject to one or more FDA food safety regulations, an onsite audit of the foreign supplier must consider such regulations and include a review of the supplier’s written food safety plan, if any, and its implementation, for the hazard being controlled (21 CFR 1.506(e)(1)(i)(B)). Your third-party onsite audit report of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated April 22 through 23, 2021, includes the audit procedures, the dates the audit was conducted, and the conclusions of the audit. The audit report notes multiple deficiencies by the foreign supplier, including failure to establish standards for cleaning and disinfection, insufficient periodic inspection and calibration of refrigerators and measuring instruments, insufficient identification of possible hazards, insufficient preventive measures of raw materials and hazardous factors, and lack of understanding of concepts and procedures for hazard analysis. However, the audit report does not describe, nor have you provided other documentation of, the corrective actions taken in response to these significant deficiencies. You also did not provide any documentation showing that the audit assessed compliance with FDA food safety regulations, reviewed the supplier’s written food safety plan, or was conducted by a qualified auditor.\u003C\u002Fp>\n\n\u003Cp>Additionally, as indicated above, the third-party onsite audit report found several issues with your foreign supplier’s performance. Note that when you become aware of new information about factors related to a foreign supplier’s performance and the risk posed by a food (see 21 CFR 1.505(a)(1) for a list of factors), such as the foreign supplier’s procedures, processes, and practices related to the safety of the food, applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, or the foreign supplier’s food safety history, you must promptly reevaluate the concerns associated with these factors and document your reevaluation (see 21 CFR 1.505(c)).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comment:\u003C\u002Fp>\n\n\u003Cp>During the most recent close out inspection, you stated that your Sales Manager and other personnel in your firm have received FSVP training. In addition, in your response to the Form 483a, you included several records prepared by your consultant, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide FDA with training records or certificates of FSVP course completion for the personnel in your firm or \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Note that a qualified individual must develop your FSVP and perform FSVP activities, and a qualified individual must have the education, training, or experience (or a combination thereof) necessary to perform their assigned activities, as required by 21 CFR 1.503(a). This includes any consultants you may have relied on to develop your FSVP or perform FSVP activities.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 949 Market St, Suite 602, Tacoma, WA 98402. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 633242 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSang Ki Lee\n\nRecipient Title\n\nBranch President & CEO\n\nDF Global, Inc.\n\n6221 Randolph St\n\nCommerce, CA 90040-3514\n\nUnited States\n\nSK.LEE@DAMTUH.COM\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nAugust 1, 2022\n\nWARNING LETTER\n\nRe: CMS # 633242\n\nDear Mr. Sang Ki Lee:\n\nOn March 30, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of DF Global, Inc., located at 6221 Randolph St, Commerce, CA 90040-3514. We also conducted an inspection on January 15, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: Honey Hallabong Tea, (b)(4) Ginger Lemon Tea, and (b)(4) Tea imported from (b)(4) located in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the FSVP inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\n\nWe acknowledge receipt of your response dated April 12, 2022, which stated that you have had an FSVP for all of your imported foods since February 2020 but you did not know which documents to provide during the most recent inspection. Your response also included records associated with your FSVPs for Honey Hallabong Tea, (b)(4) Ginger Lemon Tea, and (b)(4) Tea imported from (b)(4) located in (b)(4), such as copies of procedures, a certificate of HACCP Applied Establishment for (b)(4) from the (b)(4), an audit report for (b)(4) from the (b)(4), and hazard analyses for Honey Hallabong Tea, (b)(4) Ginger Lemon Tea, and (b)(4) Tea imported from (b)(4). We address your response below.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. A hazard means any biological, chemical (including radiological), or physical agent that is reasonably likely to cause illness or injury (see 21 CFR 1.500). A hazard requiring a control means a known or reasonably foreseeable hazard for which a person knowledgeable about the safe manufacturing, processing, packing, or holding of food would, based on the outcome of a hazard analysis (which includes an assessment of the probability that the hazard will occur in the absence of controls or measures and the severity of the illness or injury if the hazard were to occur), establish one or more controls or measures to significantly minimize or prevent the hazard in a food and components to manage those controls or measures (such as monitoring, corrections or corrective actions, verification, and records) as appropriate to the food, the facility, and the nature of the control or measure and its role in the facility’s food safety system (see 21 CFR 1.500). Specifically, in your hazard analysis for “Tea (powder type: (b)(4), etc),” which we understand to be for your (b)(4) Tea imported from (b)(4), located in (b)(4), you did not identify the chemical hazards of undeclared allergens or natural toxins, such as mycotoxins in peanuts and tree nuts (which includes walnuts and almonds). According to the product labels you provided during the most recent inspection, (b)(4), which are food allergens. Food allergens are reasonably likely to cause illness or injury when undeclared on the package label, such that a control is required to ensure proper labeling. Moreover, you should evaluate whether food allergen controls are required to prevent or significantly minimize allergen cross-contact in the Honey Hallabong Tea and (b)(4) Ginger Lemon Tea products manufactured by the same foreign supplier. You should also evaluate whether mycotoxins in peanuts and tree nuts are a hazard requiring a control for (b)(4) Tea. However, you did not provide any information that suggests that food allergens or mycotoxins were identified as hazards requiring a control.\n\n2. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506(e) for the products you import. For an onsite audit, you must retain documentation of each onsite audit, including the audit procedures, the dates the audit was conducted, the conclusions of the audit, any corrective actions taken in response to significant deficiencies identified during the audit, and documentation that the audit was conducted by a qualified auditor (21 CFR 1.506(e)(1)(i)(D)). For a food that is subject to one or more FDA food safety regulations, an onsite audit of the foreign supplier must consider such regulations and include a review of the supplier’s written food safety plan, if any, and its implementation, for the hazard being controlled (21 CFR 1.506(e)(1)(i)(B)). Your third-party onsite audit report of (b)(4), from the (b)(4), dated April 22 through 23, 2021, includes the audit procedures, the dates the audit was conducted, and the conclusions of the audit. The audit report notes multiple deficiencies by the foreign supplier, including failure to establish standards for cleaning and disinfection, insufficient periodic inspection and calibration of refrigerators and measuring instruments, insufficient identification of possible hazards, insufficient preventive measures of raw materials and hazardous factors, and lack of understanding of concepts and procedures for hazard analysis. However, the audit report does not describe, nor have you provided other documentation of, the corrective actions taken in response to these significant deficiencies. You also did not provide any documentation showing that the audit assessed compliance with FDA food safety regulations, reviewed the supplier’s written food safety plan, or was conducted by a qualified auditor.\n\nAdditionally, as indicated above, the third-party onsite audit report found several issues with your foreign supplier’s performance. Note that when you become aware of new information about factors related to a foreign supplier’s performance and the risk posed by a food (see 21 CFR 1.505(a)(1) for a list of factors), such as the foreign supplier’s procedures, processes, and practices related to the safety of the food, applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, or the foreign supplier’s food safety history, you must promptly reevaluate the concerns associated with these factors and document your reevaluation (see 21 CFR 1.505(c)).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\n(b)(3)(A)\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\n(b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nWe also offer the following comment:\n\nDuring the most recent close out inspection, you stated that your Sales Manager and other personnel in your firm have received FSVP training. In addition, in your response to the Form 483a, you included several records prepared by your consultant, (b)(4). However, you did not provide FDA with training records or certificates of FSVP course completion for the personnel in your firm or (b)(4). Note that a qualified individual must develop your FSVP and perform FSVP activities, and a qualified individual must have the education, training, or experience (or a combination thereof) necessary to perform their assigned activities, as required by 21 CFR 1.503(a). This includes any consultants you may have relied on to develop your FSVP or perform FSVP activities.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 949 Market St, Suite 602, Tacoma, WA 98402. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 633242 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","DF Global, Inc.","df-global-inc-633242-08012022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdf-global-inc-633242-08012022","2026-10-26T08:08:23.988115+00:00","2022-10-11","633242","Food & Beverages","Sang Ki Lee","2026-08-20T01:30:51.828+00:00","Via Express Delivery","2022-08-01",{"id":75,"raw":76,"subject":38,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":43,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":88,"body_fetched_at":89,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":86,"medical_device_id":19,"response_letter_date":19},3022,[77,78,79,37,38,13,13,13],"\u003Ctime datetime=\"2021-11-17T20:00:00Z\">11\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-17T05:00:00Z\">11\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdfw-vapor-holdings-inc-dba-vapor-lakes-inc-620297-11172021\">DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Bosse\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Brand Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>720 Valley Ridge Circle, Suite #4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lewisville\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75057\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:brendanl@vaporlakes.com\"> brendanl@vaporlakes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 17, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Bosse:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your&nbsp;submissions to the FDA and our inspection records, and determined DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at&nbsp;\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: VAPOR LAKES Blueberry 3MG\u002F30ML, VAPOR LAKES Lemonade 3MG\u002F30ML, and VAPOR LAKES Strawdairy 3MG\u002F30ML.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 14,500 products listed with FDA. FDA received your Premarket Tobacco Product Applications (PMTAs), assigned STNs PM0003453, PM0003786, and PM0003530 on September 8, 2020 and September 9, 2020. However, FDA issued a negative action for STNs PM0003453, PM0003530, and PM0003786 in the form of a Marketing Denial Order determination on September 8, 2021, which covers 380 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STNs PM0003453, PM0003530, and PM0003786 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100329, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJames Bosse\n\nRecipient Title\n\nBrand Owner\n\nDFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.\n\n720 Valley Ridge Circle, Suite #4\n\nLewisville, TX 75057\n\nUnited States\n\nbrendanl@vaporlakes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 17, 2021\n\nWARNING LETTER\n\nDear Mr. Bosse:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: VAPOR LAKES Blueberry 3MG\u002F30ML, VAPOR LAKES Lemonade 3MG\u002F30ML, and VAPOR LAKES Strawdairy 3MG\u002F30ML.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 14,500 products listed with FDA. FDA received your Premarket Tobacco Product Applications (PMTAs), assigned STNs PM0003453, PM0003786, and PM0003530 on September 8, 2020 and September 9, 2020. However, FDA issued a negative action for STNs PM0003453, PM0003530, and PM0003786 in the form of a Marketing Denial Order determination on September 8, 2021, which covers 380 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STNs PM0003453, PM0003530, and PM0003786 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100329, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.","dfw-vapor-holdings-inc-dba-vapor-lakes-inc-620297-11172021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdfw-vapor-holdings-inc-dba-vapor-lakes-inc-620297-11172021","2026-10-26T08:08:24.07184+00:00","2021-11-17","620297","James Bosse","2026-08-20T02:26:09.107+00:00",4,{"510k":92,"classification":93,"enforcement":94,"event":95,"event_backfill":96,"pma":97,"warning_letter":98},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]